Sarah Cannon Research Institute (SCRI), shared on LinkedIn:
“Over the past 20 years, Dee Anna Smith has shaped SCRI’s trajectory, the future of oncology research, and cancer care as our CEO.
Since joining SCRI in 2005, her visionary leadership has guided us through transformative milestones. From establishing our CRO to launching groundbreaking partnerships with US Oncology Research, expanding into personalized medicine, and most recently bringing Accelero to life, her entrepreneurial spirit and unwavering commitment to patient access have defined every chapter of SCRI’s journey.
The true measure of her leadership isn’t found in milestones alone. It’s in the investigators and research teams she’s inspired, the culture of collaboration she’s fostered, the partnerships that bring cutting-edge research closer to home, and the countless patients whose lives have been touched through the work our teams make possible.
As we continue advancing research and expanding access to innovative clinical trials, we’re grateful for her leadership and vision.”
Other articles featuring Dee Anna Smith on OncoDaily.
